KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Operations: 2017-2025

Historic Cash from Operations for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -$12.6 million.

  • Aquestive Therapeutics' Cash from Operations fell 6.47% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.5 million, marking a year-over-year decrease of 47.47%. This contributed to the annual value of -$35.8 million for FY2024, which is 460.49% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Cash from Operations of -$12.6 million as of Q3 2025, which was down 59.83% from -$7.9 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Cash from Operations high stood at $8.8 million for Q1 2023, and its period low was -$23.4 million during Q1 2025.
  • Its 3-year average for Cash from Operations is -$7.8 million, with a median of -$7.9 million in 2023.
  • In the last 5 years, Aquestive Therapeutics' Cash from Operations skyrocketed by 204.40% in 2022 and then tumbled by 406.18% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Operations (Quarterly) stood at -$8.1 million in 2021, then skyrocketed by 204.40% to $8.4 million in 2022, then tumbled by 158.72% to -$4.9 million in 2023, then tumbled by 31.30% to -$6.5 million in 2024, then declined by 6.47% to -$12.6 million in 2025.
  • Its last three reported values are -$12.6 million in Q3 2025, -$7.9 million for Q2 2025, and -$23.4 million during Q1 2025.